This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)

This study is currently recruiting participants.
See Contacts and Locations
Verified February 2017 by Alexion Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Alexion Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01892345
First received: June 20, 2013
Last updated: February 1, 2017
Last verified: February 2017
  Purpose
The primary objective of the study is to assess the efficacy and safety of eculizumab treatment as compared to placebo in relapsing NMO patients using a time to first relapse study design.

Condition Intervention Phase
Neuromyelitis Optica Neuromyelitis Optica Spectrum Disorder Drug: Eculizumab Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)

Resource links provided by NLM:


Further study details as provided by Alexion Pharmaceuticals:

Primary Outcome Measures:
  • Time to first relapse [ Time Frame: from baseline to end of study ]
    On-trial NMO Relapse, as defined by the protocol.


Secondary Outcome Measures:
  • Overall safety and tolerability of eculizumab [ Time Frame: from baseline to end of study ]
    Adverse events, vital signs and laboratory assessments


Estimated Enrollment: 132
Study Start Date: January 2014
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo contains the same buffer components without the active ingredient
Drug: Eculizumab

Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every two weeks 6-104

Drug: Placebo Other Names: Placebo

Other Name: Soliris
Experimental: Eculizumab

Induction Phase: 900 mg IV weekly X 4

Maintenance Phase: 1200 mg IV every 2 weeks 6-104

Drug: Eculizumab

Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every two weeks 6-104

Drug: Placebo Other Names: Placebo

Other Name: Soliris

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Male or female patients ≥ 18 years old
  2. Diagnosis of NMO or NMO spectrum disorder
  3. All patients must be NMO-IgG seropositive
  4. Clinical evidence of at least 2 relapses in last 12 months or 3 relapses in the last 24 months (with at least 1 relapse in the 12 months prior to the Screening)
  5. EDSS score ≤7
  6. Immunosuppressive therapy is allowed provided patients have been on a stable maintenance dose prior to the Screening and remain on a stable dose for the duration of the study

Key Exclusion Criteria:

  1. Use of rituximab within 3 months prior to screening
  2. Use of mitoxantrone within 3 months prior to screening
  3. Use of IVIg within 3 weeks prior to screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01892345

Contacts
Contact: Alexion Pharmaceuticals (Sponsor) 1-855-687-1988 clinicaltrials@alxn.com

  Show 127 Study Locations
Sponsors and Collaborators
Alexion Pharmaceuticals
  More Information

Additional Information:
Publications:
Responsible Party: Alexion Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01892345     History of Changes
Other Study ID Numbers: ECU-NMO-301
Study First Received: June 20, 2013
Last Updated: February 1, 2017

Keywords provided by Alexion Pharmaceuticals:
Neuromyelitis Optica
Neuromyelitis Optica Spectrum Disorder
Devic's disease, Transverse Myelitis
Optic Neuritis
relapse
eculizumab
soliris
NMO-IgG
CNS Autoimmune Disorders
Demyelinating Disorders

Additional relevant MeSH terms:
Neuromyelitis Optica
Myelitis, Transverse
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Optic Neuritis
Optic Nerve Diseases
Cranial Nerve Diseases
Demyelinating Diseases
Eye Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on June 22, 2017